Recent News

• 11.06.2025 - RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
• 11.04.2025 - RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
• 10.27.2025 - RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
• 10.22.2025 - RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
• 10.21.2025 - RAPT Therapeutics Announces Proposed Public Offering of Common Stock
• 10.20.2025 - RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
• 10.19.2025 - RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
• 09.29.2025 - RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
• 09.29.2025 - RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
• 09.29.2025 - RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Recent Filings

• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.23.2025 - 8-K Current report
• 10.22.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.20.2025 - 8-K Current report
• 10.20.2025 - EX-99.1 EX-99.1